GENinCode (LON:GENI) Hits New 1-Year Low – Should You Sell?

GENinCode Plc (LON:GENI)’s stock price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as GBX 0.75 and last traded at GBX 0.78, with a volume of 300338 shares traded. The stock had previously closed at GBX 0.78.

GENinCode Trading Up 0.3%

The business has a 50-day moving average of GBX 0.92 and a 200-day moving average of GBX 1.10. The company has a quick ratio of 15.88, a current ratio of 0.93 and a debt-to-equity ratio of 117.74. The stock has a market cap of £5.85 million, a price-to-earnings ratio of -0.37 and a beta of 0.59.

GENinCode (LON:GENI) last issued its earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share for the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%.The firm had revenue of GBX 308 million during the quarter. As a group, research analysts forecast that GENinCode Plc will post -7.1299999 earnings per share for the current year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.